share_log

Connect Biopharma Reports CBP-201 Achieved All Primary And Key Secondary Endpoints In Pivotal Atopic Dermatitis (AD) Trial In China

Benzinga Real-time News ·  Oct 4, 2022 07:03
  • All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD
  • Safety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathway
  • Data support advancing the regulatory discussions with the CDE for submitting an NDA in China
  • Conference call to discuss these data will be held today at 5:30am PDT/8:30am EDT

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced topline results for...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment